Invasive Urothelial Carcinoma — Trials

Invasive Urothelial Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

48 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 27
Recruiting: 15
Ph III recruiting: 2
Growth YoY: —
Industry share: 4%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (9)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04871529	Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL)	terminated	Phase 2	6	SWOG Cancer Research NetworkNETWORK	1	Dec 30, 2024	clinicaltrials
NCT03912818	Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer	terminated	Phase 2	7	Stanford UniversityOTHER	1